🇺🇸 FDA
Patent

US 9125821

Nanodrug targeting protein geranylgeranylation

granted A61KA61K31/216A61K31/40

Quick answer

US patent 9125821 (Nanodrug targeting protein geranylgeranylation) held by The Regents of the University of California expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/216, A61K31/40, A61K31/402, A61K31/4418